Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Key facts
- Where
- Charleston, Fremantle, Kogarah, Liverpool, Melbourne, Sydney, Westmead, and Woolloongabba, AustraliaSee the 9 sites
- Phase
- Phase 3
Where in Australia
- Charleston, New South WalesHospital not named in the registryTaking people
- FremantleHospital not named in the registryTaking people
- Kogarah, New South WalesHospital not named in the registryTaking people
- Liverpool, New South WalesHospital not named in the registryNo longer taking part
- Melbourne, VictoriaHospital not named in the registryTaking people
- Melbourne, VictoriaHospital not named in the registryNo longer taking part
- Sydney, New South WalesHospital not named in the registryTaking people
- WestmeadHospital not named in the registryNot yet recruiting
- Woolloongabba, QueenslandHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06855498EU 2024-520107-12-00
- Record updated
- 30 October 2026
- Original description
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.Read full original descriptionShow less
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Inclusion: Ability to comprehend and willingness to sign a written ICF for the study; Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment; Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator; Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements; Willingness to avoid pregnancy or fathering children as defined in the protocol; Willingness and ability to comply with the study Protocol and procedures.
Exclusion: Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study; Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:; Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab); Live, attenuated vaccine; Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug; Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study; Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class; Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; Other protocol-defined Inclusion/Exclusion Criteria may apply; Had been permanently discontinued from study treatment during the parent study; Women who are pregnant (or who are considering pregnancy) or breastfeeding.